Poster Presentations: Wednesday, November 3, 2010 |

Improving Pneumococcal Vaccination Rates in Patients With Chronic Obstructive Pulmonary Disease FREE TO VIEW

Mark C. Fok, MD; James Lan, MD; Heywood Choi, MD; Gina Tsai, MD; Benny Lau, MD; Mark Fitzgerald, MD
Author and Funding Information

Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Chest. 2010;138(4_MeetingAbstracts):451A. doi:10.1378/chest.10220
Text Size: A A A
Published online


PURPOSE: Invasive pneumococcal infection causes significant morbidity and mortality in patients with underlying lung disease. Pneumococcal vaccination has been suggested as a cost-effective means for preventing invasive disease and several organizations recommend vaccination every five years. Eligible COPD patients admitted to Vancouver General Hospital present an opportunity to vaccinate an at-risk population. We therefore conducted a quality improvement project with the aim to increase the rate of pneumococcal vaccinations by 20% in 3 months for eligible patients admitted for an exacerbation.

METHODS: We screened consecutive COPD exacerbation patients admitted to the medicine ward over a seven month period and retrospectively reviewed paper charts and electronic health records to determine pneumococcal vaccine status by the time of discharge. We implemented several plan-do-study-act (PDSA) cycles within this time period: in PDSA 1, we used an existing (but seasonal and underutilized) pneumococcal vaccination form and placed it on the front of eligible patient's charts. The second PDSA cycle involved educating nursing Clinical Management Leaders (CML's) to identify target patients and advocate for vaccination assessment. Our final PDSA cycle involved adding a pneumococcal vaccination assessment tool to the COPD exacerbation pathway.

RESULTS: The overall mean rate of pneumococcal vaccination in eligible COPD patients during the seven months was 40%. Our baseline data showed that 0/12 eligible patients were vaccinated. In PDSA 1, 29% of patients were vaccinated (4/14). In PDSA 2, 45% of patients were vaccinated (5/11) and PDSA 3 had 83% of patients vaccinated (10/12). Run charts by week and by block sampling were created to demonstrate the effects of change over time.

CONCLUSION: We improved the pneumococcal vaccination rate for eligible patients through successive PDSA cycles. Further quality improvement initiatives are required to demonstrate sustainability in the context of a larger sample size.

CLINICAL IMPLICATIONS: Effective interventions for improving vaccination rates involved permanent “champions” in the vaccination assessment stage and adding an assessment tool for pneumococcal vaccination in the COPD pathway. Organizations should look at sustainable options for improving vaccination rates.

DISCLOSURE: Mark Fok, No Financial Disclosure Information; No Product/Research Disclosure Information

12:45 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543